priors.science/reviews/cystic-fibrosis-treatment

Cystic Fibrosis Treatment

The current evidence on 16 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

16claims tracked
90primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
6 Established · 9 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Elexacaftor/tezacaftor/ivacaftor (ETI) triple therapy produces large, sustained improvements in FEV1 and reduces pulmonary exacerbations in people with CF carrying at least one F508del CFTR mutation.Eti ModulatorEstablished95%11
Ivacaftor monotherapy produces sustained improvements in FEV1, sweat chloride, and quality of life in CF patients with gating mutations (class III, particularly G551D).Early ModulatorEstablished93%8
ETI triple therapy significantly reduces sweat chloride concentration and improves nutritional status (BMI, weight gain) in F508del-carrying CF patients.Eti ModulatorEstablished92%7
Elexacaftor/tezacaftor/ivacaftor substantially reduces the frequency of pulmonary exacerbations and hospitalisation rates compared with pre-ETI standard of care.ExacerbationEstablished92%7
Inhaled DNase (dornase alfa) reduces sputum viscosity and decreases pulmonary exacerbation frequency and hospitalisation rates in CF.Lung OutcomesEstablished87%4
Inhaled hypertonic saline improves mucociliary clearance and reduces pulmonary exacerbation frequency in CF.Lung OutcomesEstablished85%5
Real-world effectiveness of ETI approximates clinical trial outcomes and extends to populations underrepresented in pivotal trials, including patients with advanced lung disease.Eti ModulatorLikely84%7
Inhaled tobramycin and aztreonam reduce Pseudomonas aeruginosa sputum density and improve FEV1 in chronically infected CF patients.MicrobiologyLikely84%4
Early aggressive antibiotic eradication of Pseudomonas aeruginosa at first isolation reduces chronic infection rates and improves long-term pulmonary outcomes in CF.MicrobiologyLikely84%5
Lumacaftor/ivacaftor (dual combination) produces modest FEV1 improvement in F508del homozygous CF patients but is substantially less effective than ETI triple therapy.Early ModulatorLikely84%6
Intravenous antibiotic combinations targeting Pseudomonas aeruginosa are the standard of care for severe CF pulmonary exacerbations requiring hospitalisation.ExacerbationLikely81%6
CFTR modulator therapy (particularly ETI) reduces the incidence and severity of CF-related diabetes by improving CFTR function in pancreatic ductal cells.Systemic OutcomesLikely80%5
Lung clearance index (LCI) is a more sensitive measure of early CF lung disease progression than FEV1 and detects treatment response in patients with preserved spirometry.Lung OutcomesLong-standingLikely79%8
Next-generation CFTR modulators (vanzacaftor/tezacaftor/deutivacaftor) achieve superior CFTR correction to ETI in in vitro studies and phase 2 clinical data, with potential for once-daily dosing.EmergingLikely72%3
mRNA and gene therapy approaches targeting CFTR restoration in class I and rare mutation CF patients represent a clinically viable strategy for the ~10% of patients who cannot benefit from current modulators.EmergingUncertain52%3
Track Cystic Fibrosis Treatment.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.